Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Theravance Biopharma (TBPH) over the last 7 years, with Q2 2025 value amounting to $50.7 million.

  • Theravance Biopharma's Shares Outstanding (Diluted Average) rose 405.97% to $50.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $50.7 million, marking a year-over-year increase of 405.97%. This contributed to the annual value of $48.8 million for FY2024, which is 1167.39% down from last year.
  • Latest data reveals that Theravance Biopharma reported Shares Outstanding (Diluted Average) of $50.7 million as of Q2 2025, which was up 405.97% from $49.7 million recorded in Q1 2025.
  • Theravance Biopharma's 5-year Shares Outstanding (Diluted Average) high stood at $76.3 million for Q2 2022, and its period low was $48.3 million during Q1 2024.
  • In the last 5 years, Theravance Biopharma's Shares Outstanding (Diluted Average) had a median value of $61.4 million in 2023 and averaged $61.4 million.
  • As far as peak fluctuations go, Theravance Biopharma's Shares Outstanding (Diluted Average) skyrocketed by 1667.47% in 2022, and later plummeted by 2485.09% in 2023.
  • Over the past 5 years, Theravance Biopharma's Shares Outstanding (Diluted Average) (Quarter) stood at $69.5 million in 2021, then grew by 5.95% to $73.6 million in 2022, then decreased by 24.85% to $55.3 million in 2023, then decreased by 11.67% to $48.8 million in 2024, then rose by 3.85% to $50.7 million in 2025.
  • Its last three reported values are $50.7 million in Q2 2025, $49.7 million for Q1 2025, and $48.8 million during Q4 2024.